- Home
- GHI vs GNFT Comparison
GHI vs GNFT Comparison
Compare GHI & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- GNFT
- Stock Information
- Founded
- GHI 1998
- GNFT 1999
- Country
- GHI United States
- GNFT France
- Employees
- GHI N/A
- GNFT N/A
- Industry
- GHI Finance: Consumer Services
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GHI Finance
- GNFT Health Care
- Exchange
- GHI Nasdaq
- GNFT Nasdaq
- Market Cap
- GHI 254.1M
- GNFT 216.7M
- IPO Year
- GHI N/A
- GNFT 2019
- Fundamental
- Price
- GHI $10.83
- GNFT $4.23
- Analyst Decision
- GHI Strong Buy
- GNFT Strong Buy
- Analyst Count
- GHI 4
- GNFT 2
- Target Price
- GHI $14.88
- GNFT $11.00
- AVG Volume (30 Days)
- GHI 41.2K
- GNFT 2.8K
- Earning Date
- GHI 11-05-2025
- GNFT 09-22-2025
- Dividend Yield
- GHI 13.64%
- GNFT N/A
- EPS Growth
- GHI N/A
- GNFT N/A
- EPS
- GHI N/A
- GNFT 0.03
- Revenue
- GHI $27,326,828.00
- GNFT $73,187,701.00
- Revenue This Year
- GHI $223.15
- GNFT $5.44
- Revenue Next Year
- GHI $5.11
- GNFT N/A
- P/E Ratio
- GHI N/A
- GNFT $135.62
- Revenue Growth
- GHI N/A
- GNFT 105.01
- 52 Week Low
- GHI $10.12
- GNFT $2.55
- 52 Week High
- GHI $14.51
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- GHI 50.30
- GNFT 54.29
- Support Level
- GHI $10.65
- GNFT $4.23
- Resistance Level
- GHI $10.90
- GNFT $4.35
- Average True Range (ATR)
- GHI 0.21
- GNFT 0.12
- MACD
- GHI 0.02
- GNFT 0.02
- Stochastic Oscillator
- GHI 61.54
- GNFT 75.35
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.